Guardion Health Sciences (GHSI) 10-Q 12 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 09, 2019
Document And Entity Information
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	0001642375
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,733,762
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 2,368,645	$ 670,948
Accounts receivable	35,920	28,203
Inventories	318,686	357,997
Prepaid expenses	132,306	47,773
Total current assets	2,855,557	1,104,921
Deposits	11,751	11,751
Property and equipment, net	303,929	274,804
Right of use asset, net	595,598
Deferred offering costs	19,000	270,000
Intangible assets, net	348,786	456,104
Goodwill	1,563,520	1,563,520
Total assets	5,698,141	3,681,100
Current liabilities
Accounts payable and accrued liabilities	300,239	413,925
Accrued expenses and deferred rent	25,000	81,412
Derivative warrant liability	78,440
Lease liability - current	125,237
Total current liabilities	528,916	495,337
Lease liability - long term	481,137
Total liabilities	1,010,053	495,337
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized
Common stock, $0.001 par value; 90,000,000 shares authorized; 22,733,762 and 20,564,328 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	22,734	20,564
Additional paid-in capital	43,735,894	37,798,562
Accumulated deficit	(39,070,540)	(34,633,363)
Total stockholders' equity	4,688,088	3,185,763
Total liabilities and stockholders' equity	$ 5,698,141	$ 3,681,100

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	22,733,762	20,564,328
Common stock, shares outstanding	22,733,762	20,564,328

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue
Total revenue	$ 260,970	$ 220,778	$ 503,508	$ 413,818
Cost of goods sold
Total cost of goods sold	97,056	87,776	190,548	167,055
Gross profit	163,914	133,002	312,960	246,763
Operating expenses
Research and development	77,688	34,320	106,716	194,708
Sales and marketing	409,409	378,750	764,028	984,464
General and administrative	2,489,011	1,034,914	3,439,633	2,714,680
Total operating expenses	2,976,108	1,447,984	4,310,377	3,893,852
Loss from operations	(2,812,194)	(1,314,982)	(3,997,417)	(3,647,089)
Other (income) expense:
Interest expense	234,065	710	251,637	1,545
Finance cost upon issuance of warrants	229,921		415,955
Change in fair value of derivative warrants	(227,832)		(227,832)
Costs associated with extension of warrant expiration dates		494,391		494,391
Total other (income) expense	236,154	495,101	439,760	495,936
Net loss	$ (3,048,348)	$ (1,810,083)	$ (4,437,177)	$ (4,143,025)
Net loss per common share - basic and diluted	$ (0.14)	$ (0.09)	$ (0.21)	$ (0.21)
Weighted average common shares outstanding - basic and diluted	22,537,943	20,164,761	21,628,758	20,161,131
Medical Foods [Member]
Revenue
Total revenue	$ 104,448	$ 79,993	$ 204,382	$ 154,294
Cost of goods sold
Total cost of goods sold	40,681	40,959	78,953	72,238
Vision Testing Diagnostics [Member]
Revenue
Total revenue	150,222	140,785	292,826	259,524
Cost of goods sold
Total cost of goods sold	53,816	46,817	109,036	94,817
Other [Member]
Revenue
Total revenue	6,300		6,300
Cost of goods sold
Total cost of goods sold	$ 2,559		$ 2,559

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 20,092	$ 33,716,140	$ (26,865,956)	$ 6,870,276
Balance, shares at Dec. 31, 2017	20,091,761
Fair value of vested stock options		777,513		777,513
Issuance of common stock - warrant exercises	$ 73	1,387		1,460
Issuance of common stock - warrant exercises, shares	73,000
Net loss			(2,333,461)	(2,333,461)
Balance at Mar. 31, 2018	$ 20,165	34,495,040	(29,199,417)	5,315,788
Balance, shares at Mar. 31, 2018	20,164,761
Balance at Dec. 31, 2017	$ 20,092	33,716,140	(26,865,956)	6,870,276
Balance, shares at Dec. 31, 2017	20,091,761
Reclass of warrant liability to equity
Net loss				(4,143,025)
Balance at Jun. 30, 2018	$ 20,165	35,266,803	(31,008,981)	4,277,987
Balance, shares at Jun. 30, 2018	20,164,761
Balance at Mar. 31, 2018	$ 20,165	34,495,040	(29,199,417)	5,315,788
Balance, shares at Mar. 31, 2018	20,164,761
Fair value of vested stock options		277,372		277,372
Fair value of warrants - extension of expiration dates		494,391		494,391
Net loss			(1,809,564)	(1,810,083)
Balance at Jun. 30, 2018	$ 20,165	35,266,803	(31,008,981)	4,277,987
Balance, shares at Jun. 30, 2018	20,164,761
Balance at Dec. 31, 2018	$ 20,564	37,798,562	(34,633,363)	3,185,763
Balance, shares at Dec. 31, 2018	20,564,328
Fair value of vested stock options		56,232		56,232
Issuance of common stock - warrant exercises	$ 293	30,957		31,250
Issuance of common stock - warrant exercises, shares	292,283
Net loss			(1,385,099)	(1,385,099)
Balance at Mar. 31, 2019	$ 20,857	37,885,751	(36,018,462)	1,888,146
Balance, shares at Mar. 31, 2019	20,856,611
Balance at Dec. 31, 2018	$ 20,564	37,798,562	(34,633,363)	3,185,763
Balance, shares at Dec. 31, 2018	20,564,328
Reclass of warrant liability to equity				$ 359,683
Fair value of common stock - conversion of notes payable and related interest, Shares				109,038
Net loss				$ (4,437,177)
Balance at Jun. 30, 2019	$ 22,734	43,735,894	(39,070,540)	4,688,088
Balance, shares at Jun. 30, 2019	22,733,762
Balance at Mar. 31, 2019	$ 20,857	37,885,751	(36,018,462)	1,888,146
Balance, shares at Mar. 31, 2019	20,856,611
Fair value of vested stock options		62,763		62,763
Issuance of common stock - warrant exercises	$ 463	100,162		100,625
Issuance of common stock - warrant exercises, shares	463,726
Fair value of vested stock options - officer and director		1,066,159		1,066,159
Reclass of warrant liability to equity		359,683		359,683
Sale of common stock	$ 1,250	3,886,750		3,888,000
Sale of common stock, Shares	1,250,000
Issuance of common stock for services	$ 55	123,947		124,002
Issuance of common stock for services, Shares	54,387
Fair value of common stock - conversion of notes payable and related interest	$ 109	250,679		250,788
Fair value of common stock - conversion of notes payable and related interest, Shares	109,038
Fair value of warrants - extension of expiration dates
Net loss			(3,052,078)	(3,048,348)
Balance at Jun. 30, 2019	$ 22,734	$ 43,735,894	$ (39,070,540)	$ 4,688,088
Balance, shares at Jun. 30, 2019	22,733,762

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating Activities
Net loss	$ (4,437,177)	$ (4,143,025)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	137,128	148,560
Amortization of debt discount	250,000
Accrued interest expense included in notes payable	788
Amortization of right of use asset	61,571
Stock-based compensation	242,996	1,054,885
Stock-based compensation - officer and director	1,066,159
Non-cash financing costs - derivative liability	415,955
Change in fair value of warrants - derivative liability	(227,832)
Costs associated with extension of warrant expiration dates		494,391
(Increase) decrease in -
Accounts receivable	(7,718)	42,928
Inventories	39,311	(257,627)
Deposits and prepaid expenses	(84,533)	90,053
Lease liability	(56,844)
Increase (decrease) in -
Accounts payable and accrued expenses	156,314	146,202
Accrued expenses and deferred rent	(49,814)	(425)
Net cash used in operating activities	(2,493,696)	(2,424,058)
Investing Activities
Purchase of property and equipment	(58,934)	(137,073)
Purchase of intellectual property		(50,000)
Net cash used in investing activities	(58,934)	(187,073)
Financing Activities
Proceeds from initial public offering	3,888,000
Proceeds from issuance of convertible notes	250,000
Proceeds from issuance of promissory note	100,000
Payments on promissory note	(100,548)
Payments on line of credit		(30,535)
Proceeds from exercise of warrants	131,875	1,460
Deferred financing costs of IPO	(19,000)
Decrease in due to related parties		(28,659)
Net cash provided by (used in) financing activities	4,250,327	(57,734)
Cash:
Net decrease	1,697,697	(2,668,865)
Balance at beginning of period	670,948	4,735,230
Balance at end of period	2,368,645	2,066,365
Supplemental disclosure of cash flow information:
Interest
Income taxes
Non-cash financing activities:
Fair value of warrant liability issued in connection with issuance of convertible notes	436,034
Recording of lease asset and liability upon adoption of ASU 2016-02	663,218
Reclass of warrant liability to equity	359,683
Fair value of common stock issued upon conversion of common stock and accrued interest	250,788
Reclass of deferred offering cost to equity	$ 270,000

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Organization and Business Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. The Company is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z ® The Company also developed a proprietary medical device called the MapcatSF ® ® ® On September 29, 2017, the Company, through its wholly owned subsidiary VectorVision Ocular Health, Inc. (“VectorVision”), completed its acquisition of substantially all of the assets and certain liabilities of VectorVision, Inc. (an Ohio corporation), a company that specialized in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study (“ETDRS”) visual acuity testing. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing. The acquisition expands the Company’s technical portfolio. CSV-1000 and CSV-2000 instruments offer auto-calibrated tests to ensure correct testing luminance and contrast levels for consistent, highly accurate and repeatable results. Recently issued patents the Company received for continuously calibrating the light source will be incorporated into the new CSV-2000, in which the proprietary standardized contrast sensitivity test patterns can be presented to the patient using a computer monitor as opposed to the current calibrated backlit system. In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”). TDSI is dedicated to the pursuit of early predictors resulting in, the Company believes, valuable therapeutic intervention for practitioners and their patients, and additional revenue streams generated from the testing and sale of Company products to appropriate customers. The Company has established operations with selected clinics and is focusing on expanding its client base. In November 2018, the Company launched a new medical food product, GlaucoCetin TM TM TM TM TM On April 9, 2019, the Company closed its initial public offering (the “IPO”) The Company has had limited operations to date and has been primarily engaged in research and development, product commercialization and capital raising activities. Going Concern and Liquidity The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $4,437,177 and utilized cash in operating activities of $2,493,696 during the six months ended June 30, 2019. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are issued. The Company’s independent registered public accounting firm has also included explanatory language in their opinion accompanying the Company’s audited financial statements for the year ended December 31, 2018. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company will continue to incur significant expenses for commercialization activities related to its medical foods, the MapcatSF medical device, VectorVision diagnostic equipment, the TDSI business and with respect to efforts to continue to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is seeking to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations. Reverse Stock Split On January 30, 2019, following stockholder and Board approval, the Company filed a Certificate of Amendment to its Amended Certificate of Incorporation, as amended (the “Amendment”), with the Secretary of State of the State of Delaware to effectuate a one-for-two (1:2) reverse stock split (the “Reverse Stock Split”) of its common stock, par value $0.001 per share, without any change to its par value. The Amendment became effective on the filing date. The number of shares authorized for common and preferred stock were not affected by the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split as all fractional shares were “rounded up” to the next whole share. Proportional adjustments for the Reverse Stock Split were made to all share and per share amounts as if the split occurred at the beginning of the earliest period presented.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC. The condensed consolidated balance sheet as of December 31, 2018 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2019. Certain prior period amounts have been reclassified to conform to current period presentation. Such amounts consist of operating segment disclosures, whereby revenue and cost of goods sold have been broken out on the Consolidated Statements of Operations to conform with the Company’s reportable business segments as of June 30, 2019. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Intangible Assets In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships. In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. Its goodwill and other intangible assets are subject to periodic impairment testing. The Company utilized the services of an independent third-party valuation firm to assist in identifying intangible assets and in estimating their fair values. The useful lives for the Company’s intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis. Amortization expense for the identifiable intangible assets associated with the VectorVision acquisition is approximately $54,000 per quarter and is included with general and administrative expenses in the Company’s Statements of Operations. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, identifiable intangible assets, and goodwill for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of June 30, 2019 and December 31, 2018, the Company had not deemed any long-lived assets as impaired and was not aware of the existence of any indicators of impairment at such dates. Deferred Offering Costs Deferred offering costs consist principally of legal, accounting, and underwriters’ fees incurred related to the equity financings. These deferred offering costs will be charged against the gross proceeds received during the appropriate period. During the period ended June 30, 2019, $270,000 of offering costs deferred at December 31, 2018 were offset to paid in capital upon completion of our April 2019 offering. As of June 30, 2019, $19,000 of costs have been deferred relating to offerings in process. Revenue Recognition The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally. Tthe Company recognizes revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606) Under the guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied. All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. The following table presents the Company’s revenues disaggregated by segment: Six Months Ended 2019 2018 Medical foods $ 204,382 $ 154,294 Vision testing diagnostics 292,826 259,524 Other 6,300 - $ 503,508 $ 413,818 Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures are expensed as incurred and totaled $106,716 and $194,708 for the six months ended June 30, 2019 and 2018, respectively. Patent Costs The Company is the owner of three issued domestic patents, three pending domestic patent applications, one issued foreign patent in Europe, one issued foreign patent in Hong Kong, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the six months ended June 30, 2019 and 2018, patent costs were $61,482 and $34,298, respectively, and are included in general and administrative costs in the statements of operations. Leases Prior to January 1, 2019, the Company accounted for leases under Accounting Standards Codification (ASC) 840, Accounting for Leases. Effective from January 1, 2019, the Company adopted the guidance of ASU 2016-02 (ASC 842), Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods. The adoption of ASC 842 on January 1, 2019 resulted in the recognition of operating lease right-of-use assets of $626,667, lease liabilities for operating leases of $635,131, and a zero cumulative-effect adjustment to accumulated deficit. See Note 8 for further information regarding the impact of the adoption of ASC 842 on the Company’s financial statements. Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, and employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. In prior periods, the Company accounted for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. On January 1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-07 which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The adoption of the new standard had no cumulative effect on previously reported amounts. Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: June 30, 2019 2018 Warrants 261,538 2,656,423 Options 2,612,500 2,625,000 2,874,038 5,281,423 Recent Accounting Pronouncements The Company’s management does not believe that there are any recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	3. Segment Reporting The Company determined its reporting units in accordance with ASC 280, “Segment Reporting” (“ASC 280”). The Company historically has reported its operating results as a single reportable segment described as the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Company’s chief executive officer, who is the Chief Operating Decision Maker (“CODM”), has historically reviewed financial information on an aggregated basis for purposes of allocating resources and evaluating financial performance. In September 2017, the Company, through its wholly-owned subsidiary VectorVision Ocular Health, Inc., acquired substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specialized in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study (“ETDRS”) visual acuity testing. In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”). The Company has established TDSI operations with selected clinics and is focusing on expanding its client base. Although all of the Company’s products and services target the early detection, intervention and monitoring of a range of eye diseases, the addition of potential new products or services as the Company grows requires management to periodically reevaluate its reporting structure. As sales of our medical food as well as sales of VectorVision products grow, there is an increased need for the CODM to evaluate revenue and gross profit on a product line or group basis for purposes of resource allocation. As of June 30, 2019, the TDSI subsidiary does not meet the required quantitative criteria to be considered a reportable operating segment. Additionally, TDSI does not share similar economic characteristics or a majority of the aggregation criteria set forth in ASC 280, and therefore is included in the category “Other” below. The TDSI business earned $6,300 of service revenue during the quarter ended June 30, 2019 and incurred approximately $121,000 of operating costs during the six months ended June 30, 2019. As of June 30, 2019, based on anticipated growth and the expanding diversity of product and service offerings by the Company, management has concluded that results should be reported in two operating segments: Medical Foods and Vision Testing Diagnostics. The following tables set forth our results of operations by segment (results allocated to Other consist of non-cash stock compensation expense, depreciation and amortization, corporate legal fees, and the TDSI operations): For the Three Months Ended June 30, 2019 Other Medical Foods Vision Testing Total Revenue $ 6,300 $ 104,448 $ 150,222 $ 260,970 Cost of goods sold 2,559 40,681 53,816 97,056 Gross profit 3,741 63,767 96,406 163,914 Operating expenses 1,594,719 1,175,027 206,362 2,976,108 Loss from operations $ (1,590,978 ) $ (1,111,260 ) $ (109,956 ) $ (2,812,194 ) For the Three Months Ended June 30, 2018 Other Medical Foods Vision Testing Total Revenue $ - $ 79,993 $ 140,785 $ 220,778 Cost of goods sold - 40,959 46,817 87,776 Gross profit - 39,034 93,968 133,002 Operating expenses 468,630 893,925 85,429 1,447,984 Loss from operations $ (468,630 ) $ (854,891 ) $ 8,539 $ (1,314,982 ) For the Six Months Ended June 30, 2019 Other Medical Foods Vision Testing Total Revenue $ 6,300 $ 204,382 $ 292,826 $ 503,508 Cost of goods sold 2,559 78,953 109,036 190,548 Gross profit 3,741 125,429 183,790 312,960 Operating expenses 1,959,838 2,003,320 347,219 4,310,377 Loss from operations $ (1,956,097 ) $ (1,877,891 ) $ (163,429 ) $ (3,997,417 ) For the Six Months Ended June 30, 2018 Other Medical Foods Vision Testing Total Revenue $ - $ 154,294 $ 259,524 $ 413,818 Cost of goods sold - 72,238 94,817 167,055 Gross profit - 82,056 164,707 246,763 Operating expenses 1,523,133 2,206,967 163,752 3,893,852 Loss from operations $ (1,523,133 ) $ (2,124,911 ) $ 955 $ (3,647,089 ) The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of June 30, 2019 Other Medical Foods Vision Testing Total Current assets Cash $ 13,355 $ 2,300,973 $ 54,317 $ 2,368,645 Inventories - 206,876 111,810 318,686 Other 6,300 129,983 31,943 168,226 Total current assets 19,655 2,637,832 198,070 2,855,557 Right to use asset 595,598 - - 595,598 Property and equipment, net - 294,829 9,100 303,929 Deferred offering 19,000 - - 19,000 Intangible assets, net 348,786 - - 348,786 Goodwill 1,563,520 - - 1,563,520 Other - 11,751 - 11,751 Total assets $ 2,546,559 $ 2,944,412 $ 207,170 $ 5,698,141 As of December 31, 2018 Other Medical Foods Vision Testing Total Current assets Cash $ - $ 552,613 $ 118,335 $ 670,948 Inventories - 235,957 122,040 357,997 Other - 44,110 31,866 75,976 Total current assets - 832,680 272,241 1,104,921 Property and equipment, net - 264,178 10,626 274,804 Deferred offering 270,000 - - 270,000 Intangible assets, net 456,104 - - 456,104 Goodwill 1,563,520 - - 1,563,520 Other - 11,751 - 11,751 Total assets $ 2,289,624 $ 1,108,609 $ 282,867 $ 3,681,100

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consisted of the following: June 30, December 31, 2019 2018 Raw materials $ 248,021 $ 282,574 Finished goods 70,665 75,423 $ 318,686 $ 357,997

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, net Property and equipment consisted of the following: June 30, December 31, 2019 2018 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 300,448 249,447 Furniture and fixtures 171,121 163,186 Computer equipment 64,976 64,976 Office equipment 8,193 8,193 643,095 584,159 Less accumulated depreciation and amortization (339,166 ) (309,355 ) $ 303,929 $ 274,804 For the six months ended June 30, 2019 and 2018, depreciation and amortization expense was $29,810 and $41,243, respectively, of which $0 and $15,376 was included in research and development expense, $19,065 and $4,138 was included in sales and marketing expense, and $10,745 and $21,729 was included in general and administrative expense, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets The Company’s intangible assets, including finite-lived intangible assets and $50,000 of non-amortizable purchased intellectual property, consisted of the following: June 30, December 31, 2019 2018 Customer relationships $ 430,700 $ 430,700 Technology 161,100 161,100 Trade Names 115,600 115,600 Noncompetition 17,000 17,000 724,400 724,400 Less accumulated amortization (375,614 ) (268,296 ) $ 348,786 $ 456,104 The Company’s amortization expense on its finite-lived intangible assets was $107,318 and $107,318 for the six months ended June 30, 2019 and 2018, respectively. The Company estimates future amortization expense on its finite-lived intangible assets as of June 30, 2019 to be as follows: For Years Ended December 31, 2019 $ 107,318 2020 165,320 2021 16,307 2022 9,840 $ 298,785

Promissory Notes

Promissory Notes	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Promissory Notes	7. Promissory Notes Promissory Note On March 12, 2019, the Company issued a promissory note with principal in the amount of $100,000, simple interest of 10% annually, and with a maturity date of June 10, 2019. On April 11, 2019, the Company repaid the promissory note for a total of $100,548 including accrued interest. Convertible Notes and Related Warrants On March 15, 2019, the Company issued a convertible note with principal in the amount of $100,000, simple interest of 5% annually, and with a maturity date of September 30, 2019. In addition, on March 20, 2019, the Company issued a convertible note with principal in the amount of $150,000, simple interest of 5% annually, and with a maturity date of September 30, 2019. The convertible notes (principal and accrued interest) were mandatorily convertible upon the consummation of the IPO. Concurrent with the issuance of the notes, the Company issued warrants to both note holders equal to the number of shares of common stock that the holders receive in connection with the converted notes. The per share exercise price of the warrants was set at 125% of the conversion price of the notes, defined in the note agreements, as the lower of (a) 75% of the price per share of common stock of the IPO or (b) $2.30. The Company determined that it would have to issue 109,038 warrants based upon the completion of the IPO in April 2019 Due to the variable terms of both the exercise price and the number of warrants to be issued, the warrants were accounted for as derivative liabilities at March 31, 2019. The aggregate fair value of the warrants was calculated as $436,034 based on a probability effected Black-Scholes option pricing model with a stock price of $4.00, volatility of 138%, and risk-free rates ranging from 2.34% - 2.39%. The Company recognized a debt discount of $250,000 equal to the face amount of the convertible notes and recorded a financing cost of $186,034 equal to the difference between the fair value of the warrants and the debt discount. The convertible notes and accrued interest with an aggregate balance of $250,788 were mandatorily converted into 109,038 shares of common stock based on a conversion price of $2.30 per share upon the consummation of the IPO in April 2019.and the valuation discount of $250,000 was recognized as interest cost.

Lease Liabilities

Lease Liabilities	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Lease Liabilities	8. Lease Liabilities In October 2012, the Company entered into a lease agreement for 9,605 square feet of office and warehouse space commencing March 1, 2013. Upon entering into the agreement, the Company paid a deposit of $47,449, of which $36,979 represented prepaid rent. As of June 30, 2019, $11,751 remained on deposit under the lease agreement. The lease (“Lease 1”) was renewed for an additional five years in 2018. As of June 30, 2019, remaining average monthly lease payments under the amended lease agreement were $12,915 through July 2023. In connection with the VectorVision acquisition on September 29, 2017, the Company assumed a lease agreement for 5,000 square feet of office and warehouse space which commenced on October 1, 2017. The lease (“Lease 2”) was renewed for an additional 65 months. As of June 30, 2019, remaining average monthly lease payments are $1,838 through February 2023. In accounting for the leases, the Company adopted ASU 2016-02 - Leases, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the leases as operating leases and determined that the fair value of Lease 1 at the inception of the lease was $625,778 using a discount rate of 8.0%. the fair value of Lease 2 at the inception of the lease was $100,742 using a discount rate of 8%. During the six months ended June 30, 2019, the Company made combined payments on both leases of $82,434 towards the lease liabilities. As of June 30, 2019 and December 31, 2018, the lease liability for Lease 1 was $536,672 and $586,082, respectively, and the lease liability for Lease 2 was $69,703 and $77,137, respectively. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Combined rent expense for both leases for the six months ended June 30, 2019 and 2018 was $87,161 and $10,671, respectively. During the six months ended June 30, 2019 and 2018, the Company reflected amortization of right of use asset of $61,571 and $7,152 related to the leases, respectively, resulting in a net asset balance of $595,598 as of June 30, 2019.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	9. Contingencies The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s financial statements at June 30, 2019 with respect to such matters.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity (Deficit)	10. Stockholders’ Equity (Deficit) Warrants A summary of the Company’s warrant activity is as follows: Shares Weighted Exercise Price Weighted December 31, 2018 1,265,674 0.71 0.29 Granted 171,538 2.39 3.11 Forfeitures - - - Expirations (279,424 ) (1.96 ) - Exercised (896,250 ) (1.88 ) - June 30, 2019, all exercisable 261,538 $ 2.81 3.35 The exercise prices of warrants outstanding and exercisable as of June 30, 2019 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 25,000 $ 0.50 65,000 1.50 109,038 2.88 62,500 5.00 261,538 Between February 11, 2019 and May 21, 2019, investors net exercised a total of 632,500 warrants for 492,256 shares of common stock on a cashless basis. Between February 11, 2019 and May 21, 2019, investors exercised warrants for 263,750 shares of common stock. The warrants were exercisable for $0.50 per share, and the Company received $131,875 in cash. As of June 30, 2019, the Company had an aggregate of 261,538 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $2.81, a weighted average remaining life of 3.35 years and an aggregate intrinsic value of $19,000, based upon a stock valuation of $1.26 per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants. Warrant liability In March 2019, the Company issued warrants to two convertible note holders pursuant to the anticipated completion of the Company’s IPO (the IPO was completed on April 9, 2019). Due to the variable terms of both the exercise price and the number of warrants to be issued, the warrants were accounted for as derivative liabilities at March 31, 2019. At March 31, 2019, the Company estimated that the issuance of 109,038 warrants with an exercise price of $2.88 per share would correspond to the number of shares of common stock that the holders would receive in connection with the completion of the IPO.. The fair value of the warrants at the closing of the IPO was determined to be $359,683 using a Black-Scholes model with a weighted average remaining life of 4.94 years and a stock valuation of $3.30 per share. Upon completion of the IPO, the exercise price and the number of warrants were fixed and the warrants no longer accounted for as liabilities. As such the fair value of the warrant liability of $359,683 was reclassified to equity. On April 4, 2019, the Company issued 62,500 warrants with an exercise price of $5.00 per share to the underwriter (the “Underwriter”) in connection with the Company’s IPO. The Company accounted for these warrants as a derivative liability in the financial statements at June 30, 2019 because they were associated with the IPO, a registered offering, and the settlement provisions contained language that the shares underlying the warrants are required to be registered. The fair value of the warrants is remeasured at each reporting period, and the change in the fair value is recognized in earnings in the accompanying Statements of Operations. The fair value of the warrants at the date of issuance was determined to be $229,291 and was recorded as a finance cost. As of June 30, 2019, the fair value of the warrants was determined to $78,440. The fair value of the warrant liability was determined at the following issuance and reporting dates using the Black-Scholes-Merton option pricing model and the following assumptions: Convertible Noteholders Underwriter Warrant Liability As of Upon Issuance Upon Issuance June 30, 2019 Stock price $ 4.00 $ 3.68 $ 1.26 Risk free interest rate 2.34 – 2.39 % 2.29 % 1.71 % Expected volatility 138 % 137 % 145 % Expected life in years 5.00 5.00 4.76 Expected dividend yield 0 % 0 % 0 % Number of warrants 109,038 62,500 62,500 Fair value of warrants $ 436,034 $ 229,921 $ 78,440 Stock Options A summary of the Company’s stock option activity is as follows: Shares Weighted Average Weighted Average Remaining Contractual Term (Years) December 31, 2018 1,362,500 2.26 3.78 Granted 1,250,000 2.11 2.29 Forfeitures - - - Expirations - - - Exercised - - - June 30, 2019, outstanding 2,612,500 $ 3.28 4.00 June 30, 2019, exercisable 1,391,667 $ 2.41 3.46 The exercise prices of options outstanding and exercisable as of June 30, 2019 are as follows: Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 625,000 625,000 $ 2.00 62,500 62,500 2.30 675,000 600,000 2.50 1,250,000 104,167 4.40 2,612,500 1,391,667 During the six months ended June 30, 2019, the Company granted options to purchase 1,250,000 shares of common stock to the Company’s Chairman and CEO with a grant date fair of $4,122,750. The options will vest on a quarterly basis over three years. The Company accounts share-based payments to employees in accordance with ASC 718 wherein grants are measured at the grant date fair value and charged to operations over the vesting period. During the period ended June 30, 2019, compensation cost of $1, 066,159 was recognized during the period relating the amortization of this award. During the period ended June 30, 2019, option awards were valued based upon the Black-Scholes option-pricing model, with stock price ranging from $3.30 to $4.00 per share, volatility ranging from 115% to 138%, and an average risk-free rate ranging from 2.31% to 2.46%. During the six months ended June 30, 2019 and 2018, we recognized aggregate stock-compensation expense of $1,309,155 and $1,054,885, respectively, based upon stock prices ranging from $3.30 to $4.00 per share, all of which was recorded in general and administrative expense. As of June 30, 2019, the Company had an aggregate of 1,220,833 remaining unvested options outstanding, with a total estimated fair value of $3,132,532, weighted average exercise price of $4.28, and weighted average remaining life of 4.61 years. The aggregate intrinsic value of options outstanding as of June 30, 2019 was $0.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions During the six months ended June 30, 2019 and 2018, the Company incurred and paid $150,000 and 137,500, respectively, of salary expense to our Board Chairman and CEO, Mr. Michael Favish. In addition, compensation cost of $1,066,159 was recognized on amortization of stock option awards during the period ended June 30, 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC. The condensed consolidated balance sheet as of December 31, 2018 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2019. Certain prior period amounts have been reclassified to conform to current period presentation. Such amounts consist of operating segment disclosures, whereby revenue and cost of goods sold have been broken out on the Consolidated Statements of Operations to conform with the Company’s reportable business segments as of June 30, 2019.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.
Intangible Assets	Intangible Assets In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships. In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. Its goodwill and other intangible assets are subject to periodic impairment testing. The Company utilized the services of an independent third-party valuation firm to assist in identifying intangible assets and in estimating their fair values. The useful lives for the Company’s intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis. Amortization expense for the identifiable intangible assets associated with the VectorVision acquisition is approximately $54,000 per quarter and is included with general and administrative expenses in the Company’s Statements of Operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, identifiable intangible assets, and goodwill for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of June 30, 2019 and December 31, 2018, the Company had not deemed any long-lived assets as impaired and was not aware of the existence of any indicators of impairment at such dates.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs consist principally of legal, accounting, and underwriters’ fees incurred related to the equity financings. These deferred offering costs will be charged against the gross proceeds received during the appropriate period. During the period ended June 30, 2019, $270,000 of offering costs deferred at December 31, 2018 were offset to paid in capital upon completion of our April 2019 offering. As of June 30, 2019, $19,000 of costs have been deferred relating to offerings in process.
Revenue Recognition	Revenue Recognition The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally. Tthe Company recognizes revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606) Under the guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied. All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. The following table presents the Company’s revenues disaggregated by segment: Six Months Ended 2019 2018 Medical foods $ 204,382 $ 154,294 Vision testing diagnostics 292,826 259,524 Other 6,300 - $ 503,508 $ 413,818
Research and Development Costs	Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures are expensed as incurred and totaled $106,716 and $194,708 for the six months ended June 30, 2019 and 2018, respectively.
Patent Costs	Patent Costs The Company is the owner of three issued domestic patents, three pending domestic patent applications, one issued foreign patent in Europe, one issued foreign patent in Hong Kong, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the six months ended June 30, 2019 and 2018, patent costs were $61,482 and $34,298, respectively, and are included in general and administrative costs in the statements of operations.
Leases	Leases Prior to January 1, 2019, the Company accounted for leases under Accounting Standards Codification (ASC) 840, Accounting for Leases. Effective from January 1, 2019, the Company adopted the guidance of ASU 2016-02 (ASC 842), Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods. The adoption of ASC 842 on January 1, 2019 resulted in the recognition of operating lease right-of-use assets of $626,667, lease liabilities for operating leases of $635,131, and a zero cumulative-effect adjustment to accumulated deficit. See Note 8 for further information regarding the impact of the adoption of ASC 842 on the Company’s financial statements.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, and employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. In prior periods, the Company accounted for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. On January 1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-07 which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The adoption of the new standard had no cumulative effect on previously reported amounts.
Net Loss Per Share	Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: June 30, 2019 2018 Warrants 261,538 2,656,423 Options 2,612,500 2,625,000 2,874,038 5,281,423
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company’s management does not believe that there are any recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by segment: Six Months Ended 2019 2018 Medical foods $ 204,382 $ 154,294 Vision testing diagnostics 292,826 259,524 Other 6,300 - $ 503,508 $ 413,818
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: June 30, 2019 2018 Warrants 261,538 2,656,423 Options 2,612,500 2,625,000 2,874,038 5,281,423

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following tables set forth our results of operations by segment (results allocated to Other consist of non-cash stock compensation expense, depreciation and amortization, corporate legal fees, and the TDSI operations): For the Three Months Ended June 30, 2019 Other Medical Foods Vision Testing Total Revenue $ 6,300 $ 104,448 $ 150,222 $ 260,970 Cost of goods sold 2,559 40,681 53,816 97,056 Gross profit 3,741 63,767 96,406 163,914 Operating expenses 1,594,719 1,175,027 206,362 2,976,108 Loss from operations $ (1,590,978 ) $ (1,111,260 ) $ (109,956 ) $ (2,812,194 ) For the Three Months Ended June 30, 2018 Other Medical Foods Vision Testing Total Revenue $ - $ 79,993 $ 140,785 $ 220,778 Cost of goods sold - 40,959 46,817 87,776 Gross profit - 39,034 93,968 133,002 Operating expenses 468,630 893,925 85,429 1,447,984 Loss from operations $ (468,630 ) $ (854,891 ) $ 8,539 $ (1,314,982 ) For the Six Months Ended June 30, 2019 Other Medical Foods Vision Testing Total Revenue $ 6,300 $ 204,382 $ 292,826 $ 503,508 Cost of goods sold 2,559 78,953 109,036 190,548 Gross profit 3,741 125,429 183,790 312,960 Operating expenses 1,959,838 2,003,320 347,219 4,310,377 Loss from operations $ (1,956,097 ) $ (1,877,891 ) $ (163,429 ) $ (3,997,417 ) For the Six Months Ended June 30, 2018 Other Medical Foods Vision Testing Total Revenue $ - $ 154,294 $ 259,524 $ 413,818 Cost of goods sold - 72,238 94,817 167,055 Gross profit - 82,056 164,707 246,763 Operating expenses 1,523,133 2,206,967 163,752 3,893,852 Loss from operations $ (1,523,133 ) $ (2,124,911 ) $ 955 $ (3,647,089 ) The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of June 30, 2019 Other Medical Foods Vision Testing Total Current assets Cash $ 13,355 $ 2,300,973 $ 54,317 $ 2,368,645 Inventories - 206,876 111,810 318,686 Other 6,300 129,983 31,943 168,226 Total current assets 19,655 2,637,832 198,070 2,855,557 Right to use asset 595,598 - - 595,598 Property and equipment, net - 294,829 9,100 303,929 Deferred offering 19,000 - - 19,000 Intangible assets, net 348,786 - - 348,786 Goodwill 1,563,520 - - 1,563,520 Other - 11,751 - 11,751 Total assets $ 2,546,559 $ 2,944,412 $ 207,170 $ 5,698,141 As of December 31, 2018 Other Medical Foods Vision Testing Total Current assets Cash $ - $ 552,613 $ 118,335 $ 670,948 Inventories - 235,957 122,040 357,997 Other - 44,110 31,866 75,976 Total current assets - 832,680 272,241 1,104,921 Property and equipment, net - 264,178 10,626 274,804 Deferred offering 270,000 - - 270,000 Intangible assets, net 456,104 - - 456,104 Goodwill 1,563,520 - - 1,563,520 Other - 11,751 - 11,751 Total assets $ 2,289,624 $ 1,108,609 $ 282,867 $ 3,681,100

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following: June 30, December 31, 2019 2018 Raw materials $ 248,021 $ 282,574 Finished goods 70,665 75,423 $ 318,686 $ 357,997

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following: June 30, December 31, 2019 2018 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 300,448 249,447 Furniture and fixtures 171,121 163,186 Computer equipment 64,976 64,976 Office equipment 8,193 8,193 643,095 584,159 Less accumulated depreciation and amortization (339,166 ) (309,355 ) $ 303,929 $ 274,804

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The Company’s intangible assets, including finite-lived intangible assets and $50,000 of non-amortizable purchased intellectual property, consisted of the following: June 30, December 31, 2019 2018 Customer relationships $ 430,700 $ 430,700 Technology 161,100 161,100 Trade Names 115,600 115,600 Noncompetition 17,000 17,000 724,400 724,400 Less accumulated amortization (375,614 ) (268,296 ) $ 348,786 $ 456,104
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The Company estimates future amortization expense on its finite-lived intangible assets as of June 30, 2019 to be as follows: For Years Ended December 31, 2019 $ 107,318 2020 165,320 2021 16,307 2022 9,840 $ 298,785

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of Warrants Activity	A summary of the Company’s warrant activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2018 1,265,674 0.71 0.29 Granted 171,538 2.39 3.11 Forfeitures - - - Expirations (279,424 ) (1.96 ) - Exercised (896,250 ) (1.88 ) - June 30, 2019, all exercisable 261,538 $ 2.81 3.35
Schedule of Exercise Price of Warrants Outstanding and Exercisable	The exercise prices of warrants outstanding and exercisable as of June 30, 2019 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 25,000 $ 0.50 65,000 1.50 109,038 2.88 62,500 5.00 261,538
Schedule of Fair Value Assumptions of Warrant Liability	The fair value of the warrant liability was determined at the following issuance and reporting dates using the Black-Scholes-Merton option pricing model and the following assumptions: Convertible Noteholders Underwriter Warrant Liability As of Upon Issuance Upon Issuance June 30, 2019 Stock price $ 4.00 $ 3.68 $ 1.26 Risk free interest rate 2.34 – 2.39 % 2.29 % 1.71 % Expected volatility 138 % 137 % 145 % Expected life in years 5.00 5.00 4.76 Expected dividend yield 0 % 0 % 0 % Number of warrants 109,038 62,500 62,500 Fair value of warrants $ 436,034 $ 229,921 $ 78,440
Schedule of Share-based Compensation, Stock Options, Activity	A summary of the Company’s stock option activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2018 1,362,500 2.26 3.78 Granted 1,250,000 2.11 2.29 Forfeitures - - - Expirations - - - Exercised - - - June 30, 2019, outstanding 2,612,500 $ 3.28 4.00 June 30, 2019, exercisable 1,391,667 $ 2.41 3.46
Schedule of Exercise Price of Options Outstanding and Exercisable	The exercise prices of options outstanding and exercisable as of June 30, 2019 are as follows: Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 625,000 625,000 $ 2.00 62,500 62,500 2.30 675,000 600,000 2.50 1,250,000 104,167 4.40 2,612,500 1,391,667

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($)	Apr. 09, 2019	Jan. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Net proceeds from offering							$ 3,888,000
Debt conversion, converted instrument, shares issued							109,038
Net loss			$ (3,048,348)	$ (1,385,099)	$ (1,810,083)	$ (2,333,461)	$ (4,437,177)	(4,143,025)
Cash utilized in operating activities							$ (2,493,696)	$ (2,424,058)
Reverse stock split		one-for-two (1:2) reverse stock split
Common stock par value		$ 0.001
IPO [Member]
Initial public offering number of shares issued	1,250,000
Shares issued price per share	$ 4
Gross proceeds from initial public offering	$ 5,000,000
Net proceeds from offering	$ 3,888,000
Debt conversion, converted instrument, shares issued	109,038
Debt conversion price	$ 2.30

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 02, 2019	Dec. 31, 2018
Amortization of intangible assets			$ 107,318	$ 107,318
Deferred offering costs	$ 19,000		19,000
Research and development costs	77,688	$ 34,320	106,716	194,708
Patent costs	61,482	$ 34,298	61,482	$ 34,298
Operating lease right-of-use assets	595,598		595,598		$ 626,667
Lease liabilities for operating leases					635,131
Cumulative- effect adjustment to accumulated deficit					$ 0
April 2019 Offering [Member]
Offering costs deferred offset to additional paid in capital			$ 270,000
VectorVision, Inc [Member]
Amortization of intangible assets	$ 54,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues	$ 260,970	$ 220,778	$ 503,508	$ 413,818
Medical Foods [Member]
Revenues	104,448	79,993	204,382	154,294
Vision Testing Diagnostics [Member]
Revenues	$ 150,222	$ 140,785	292,826	259,524
Other [Member]
Revenues			$ 6,300

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive securities excluded from computation of earnings per share, amount	2,874,038	5,281,423
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	261,538	2,656,423
Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount	2,612,500	2,625,000

Segment Reporting (Details Narr

Segment Reporting (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)Segment	Jun. 30, 2018USD ($)
Number of segment reporting | Segment			1
Revenue	$ 260,970	$ 220,778	$ 503,508	$ 413,818
Other [Member]
Revenue	$ 6,300		6,300
Operating costs			$ 121,000

Segment Reporting - Schedule of

Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 02, 2019	Dec. 31, 2018
Revenue	$ 260,970	$ 220,778	$ 503,508	$ 413,818
Cost of goods sold	97,056	87,776	190,548	167,055
Gross profit	163,914	133,002	312,960	246,763
Operating expenses	2,976,108	1,447,984	4,310,377	3,893,852
Loss from operations	(2,812,194)	(1,314,982)	(3,997,417)	(3,647,089)
Cash	2,368,645		2,368,645			$ 670,948
Inventories	318,686		318,686			357,997
Other	168,226		168,226			75,976
Total current assets	2,855,557		2,855,557			1,104,921
Right to use asset	595,598		595,598		$ 626,667
Property and equipment, net	303,929		303,929			274,804
Deferred offering	19,000		19,000			270,000
Intangible assets, net	348,786		348,786			456,104
Goodwill	1,563,520		1,563,520			1,563,520
Other	11,751		11,751			11,751
Total assets	5,698,141		5,698,141			3,681,100
Other [Member]
Revenue	6,300		6,300
Cost of goods sold	2,559		2,559
Gross profit	3,741		3,741
Operating expenses	1,594,719	468,630	1,959,838	1,523,133
Loss from operations	(1,590,978)	(468,630)	(1,956,097)	(1,523,133)
Cash	13,355		13,355
Inventories
Other	6,300		6,300
Total current assets	19,655		19,655
Right to use asset	595,598		595,598
Property and equipment, net
Deferred offering	19,000		19,000			270,000
Intangible assets, net	348,786		348,786			456,104
Goodwill	1,563,520		1,563,520			1,563,520
Other
Total assets	2,546,559		2,546,559			2,289,624
Medical Foods [Member]
Revenue	104,448	79,993	204,382	154,294
Cost of goods sold	40,681	40,959	78,953	72,238
Gross profit	63,767	39,034	125,429	82,056
Operating expenses	1,175,027	893,925	2,003,320	2,206,967
Loss from operations	(1,111,260)	(854,891)	(1,877,891)	(2,124,911)
Cash	2,300,973		2,300,973			552,613
Inventories	206,876		206,876			235,957
Other	129,983		129,983			44,110
Total current assets	2,637,832		2,637,832			832,680
Right to use asset
Property and equipment, net	294,829		294,829			264,178
Deferred offering
Intangible assets, net
Goodwill
Other	11,751		11,751			11,751
Total assets	2,944,412		2,944,412			1,108,609
Vision Testing Diagnostics [Member]
Revenue	150,222	140,785	292,826	259,524
Cost of goods sold	53,816	46,817	109,036	94,817
Gross profit	96,406	93,968	183,790	164,707
Operating expenses	206,362	85,429	347,219	163,752
Loss from operations	(109,956)	$ 8,539	(163,429)	$ 955
Cash	54,317		54,317			118,335
Inventories	111,810		111,810			122,040
Other	31,943		31,943			31,866
Total current assets	198,070		198,070			272,241
Right to use asset
Property and equipment, net	9,100		9,100			10,626
Deferred offering
Intangible assets, net
Goodwill
Other
Total assets	$ 207,170		$ 207,170			$ 282,867

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 248,021	$ 282,574
Finished goods	70,665	75,423
Inventory, Net	$ 318,686	$ 357,997

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Depreciation and amortization expense	$ 29,810	$ 41,243
Research and Development Expense [Member]
Depreciation and amortization expense	0	15,376
Sales and Marketing Expense [Member]
Depreciation and amortization expense	19,065	4,138
General and Administrative Expense [Member]
Depreciation and amortization expense	$ 10,745	$ 21,729

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property, plant and equipment, gross	$ 643,095	$ 584,159
Less accumulated depreciation and amortization	(339,166)	(309,355)
Property, plant and equipment, net	303,929	274,804
Leasehold Improvements [Member]
Property, plant and equipment, gross	98,357	98,357
Testing Equipment [Member]
Property, plant and equipment, gross	300,448	249,447
Furniture and Fixtures [Member]
Property, plant and equipment, gross	171,121	163,186
Computer Equipment [Member]
Property, plant and equipment, gross	64,976	64,976
Office Equipment [Member]
Property, plant and equipment, gross	$ 8,193	$ 8,193

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Non-amortizable purchased intellectual property	$ 50,000
Amortization of intangible assets	$ 107,318	$ 107,318

Intangible Assets - Schedule of

Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Finite-lived intangible assets, gross	$ 724,400	$ 724,400
Less accumulated amortization	(375,614)	(268,296)
Finite-lived intangible assets, net	298,785	456,104
Customer Relationships [Member]
Finite-lived intangible assets, gross	430,700	430,700
Technology [Member]
Finite-lived intangible assets, gross	161,100	161,100
Trade Names [Member]
Finite-lived intangible assets, gross	115,600	115,600
Noncompetition [Member]
Finite-lived intangible assets, gross	$ 17,000	$ 17,000

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2019	$ 107,318
2020	165,320
2021	16,307
2022	9,840
Finite-lived intangible assets, net	$ 298,785	$ 456,104

Promissory Notes (Details Narra

Promissory Notes (Details Narrative) - USD ($)	Apr. 11, 2019	Apr. 09, 2019	Apr. 04, 2019	Mar. 20, 2019	Mar. 15, 2019	Mar. 12, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Repayment of promissory note	$ 100,548
Aggregate fair value of warrants							$ (227,832)			$ (227,832)
Debt conversion, converted instrument, amount							$ 250,788
Debt conversion, converted instrument, shares issued										109,038
Discount recognized as interest cost										$ 788
Warrants [Member]
Aggregate fair value of warrants		$ 359,683	$ 229,291					$ 436,034		$ 78,440
Stock price		$ 3.30						$ 4
Volatility rate								138.00%
Risk-free interest rate, minimum								2.34%
Risk-free interest rate, maximum								2.39%
IPO [Member]
Number of shares entitled for warrants				109,038				109,038
Debt conversion, converted instrument, amount		$ 250,788
Debt conversion, converted instrument, shares issued		109,038
Debt conversion price		$ 2.30
Discount recognized as interest cost		$ 250,000
IPO [Member] | Warrants [Member]
Debt instrument conversion rate				125.00%
Warrants exercise price per share, description				The per share exercise price of the warrants was set at 125% of the conversion price of the notes, defined in the note agreements, as the lower of (a) 75% of the price per share of common stock of the IPO or (b) $2.30.
Promissory Note [Member]
Debt instrument principal amount						$ 100,000
Debt interest rate						10.00%
Debt instrument maturity date						Jun. 10, 2019
Convertible Note [Member]
Debt instrument principal amount				$ 150,000	$ 100,000
Debt interest rate				5.00%	5.00%
Debt instrument maturity date				Sep. 30, 2019	Sep. 30, 2019
Debt discount								$ 250,000
Financing cost								$ 186,034

Lease Liabilities (Details Narr

Lease Liabilities (Details Narrative)	1 Months Ended	6 Months Ended
	Oct. 31, 2012USD ($)ft²	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jan. 02, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 29, 2017ft²
Lease liability				$ 635,131
Rent expense		$ 87,161	$ 10,671
Amortization of right of use asset		61,571	$ 7,152
Right of use asset, net		595,598		$ 626,667
Lease 1 [Member]
Fair value of lease		$ 625,778
Lease discount rate		8.00%
Lease liability		$ 536,672			586,082
Lease 2 [Member]
Fair value of lease		$ 100,742
Lease discount rate		8.00%
Lease liability		$ 69,703			$ 77,137
Lease 1 & 2 [Member]
Monthly lease payments		82,434
Lease Agreement [Member]
Area of Land | ft²	9,605
Deposit paid for lease	$ 47,449	$ 11,751
Prepaid rent	$ 36,979
Renewal of lease term		5 years
Lease Agreement [Member] | VectorVision, Inc [Member]
Area of Land | ft²						5,000
Renewal of lease term						65 months
Lease Agreement [Member] | Through July 2023 [Member]
Monthly lease payments		$ 12,915
Lease Agreement [Member] | Through February 2023 [Member] | VectorVision, Inc [Member]
Monthly lease payments		$ 1,838

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)	Apr. 09, 2019	Apr. 04, 2019	Jun. 30, 2019	May 21, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 20, 2019
Warrant exercisable price per share		$ 5	$ 2.81				$ 2.81
Proceeds from exercise of warrants							$ 131,875	$ 1,460
Warrants outstanding			261,538				261,538
Weighted average remaining life							3 years 4 months 6 days
Warrants issued		62,500
Aggregate fair value of warrants			$ (227,832)				$ (227,832)
Shares, Granted							1,250,000
Grant date fair value of options granted							$ 4,122,750
Amortization of stock option awards							1,066,159
Stock compensation expense							242,996	1,054,885
Warrants [Member]
Weighted average remaining life	4 years 11 months 8 days
Share price	$ 3.30				$ 4
Aggregate fair value of warrants	$ 359,683	$ 229,291			$ 436,034		$ 78,440
Reclassification of fair value of warrant liability to equity	$ 359,683
IPO [Member]
Number of shares entitled for warrants					109,038				109,038
Warrant exercisable price per share					$ 2.88
Stock Option [Member]
Share price			$ 1.26				$ 1.26
Stock compensation expense							$ 1,309,155	$ 1,054,885
Number of unvested options outstanding			1,220,833				1,220,833
Number of unvested options outstanding, value			$ 3,132,532				$ 3,132,532
Unvested options, weighted average exercise price			$ 4.28				$ 4.28
Unvested options, weighted average remaining life							4 years 7 months 10 days
Unvested options, aggregate intrinsic value			$ 0				$ 0
Stock Option [Member] | Maximum [Member]
Share price			$ 4				$ 4
Volatility							138.00%
Average risk-free rates							2.46%
Stock Option [Member] | Minimum [Member]
Share price			$ 3.30				$ 3.30
Volatility							115.00%
Average risk-free rates							2.31%
Warrants [Member]
Warrants outstanding			62,500				62,500
Aggregate intrinsic value			$ 19,000				$ 19,000
Share price			$ 1.26				$ 1.26
Volatility							145.00%
Average risk-free rates							1.71%
Investors [Member] | Warrants One [Member]
Number of warrants exercised				632,500
Investors [Member] | Warrants Two [Member]
Number of warrants exercised				263,750
Investors [Member] | Warrants [Member]
Number of shares entitled for warrants				492,256
Warrant exercisable price per share				$ 0.50
Proceeds from exercise of warrants				$ 131,875

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) - Warrants [Member]	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Shares, Beginning Balance | shares	1,265,674
Shares, Granted | shares	171,538
Shares, Forfeitures | shares
Shares, Expirations | shares	(279,424)
Shares, Exercised | shares	(896,250)
Shares, Ending Balance | shares	261,538
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.71
Weighted Average Exercise Price, Granted | $ / shares	2.39
Weighted Average Exercise Price, Forfeitures | $ / shares
Weighted Average Exercise Price, Expirations | $ / shares	(1.96)
Weighted Average Exercise Price, Exercised | $ / shares	(1.88)
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 2.81
Weighted Average Remaining Contractual Term (Years), Beginning Balance	3 months 15 days
Weighted Average Remaining Contractual Term (Years), Granted	3 years 1 month 9 days
Weighted Average Remaining Contractual Term (Years), Ending Balance	3 years 4 months 6 days

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) - Schedule of Exercise Price of Warrants Outstanding and Exercisable (Details) - $ / shares	Jun. 30, 2019	Apr. 04, 2019	Dec. 31, 2018
Exercise Prices	$ 2.81	$ 5
Warrant One [Member]
Warrants Outstanding and Exercisable (Shares)	25,000
Exercise Prices	$ 0.50
Warrant Two [Member]
Warrants Outstanding and Exercisable (Shares)	65,000
Exercise Prices	$ 1.50
Warrant Three [Member]
Warrants Outstanding and Exercisable (Shares)	109,038
Exercise Prices	$ 2.88
Warrant Four [Member]
Warrants Outstanding and Exercisable (Shares)	62,500
Exercise Prices	$ 5
Warrants [Member]
Warrants Outstanding and Exercisable (Shares)	261,538		1,265,674

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) - Schedule of Fair Value Assumptions of Warrant Liability (Details)	6 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Number of warrants	261,538
Warrants [Member]
Stock price | $ / shares	$ 1.26
Risk free interest rate	1.71%
Expected volatility	145.00%
Expected life in years	4 years 9 months 3 days
Expected dividend yield	0.00%
Number of warrants	62,500
Fair value of warrants | $	$ 78,440
Convertible Noteholders Upon Issuance [Member]
Stock price | $ / shares	$ 4
Risk free interest rate, minimum	2.34%
Risk free interest rate, maximum	2.39%
Expected volatility	138.00%
Expected life in years	5 years
Expected dividend yield	0.00%
Number of warrants	109,038
Fair value of warrants | $	$ 436,034
Underwriter LLC Upon Issuance [Member]
Stock price | $ / shares	$ 3.68
Risk free interest rate	2.29%
Expected volatility	137.00%
Expected life in years	5 years
Expected dividend yield	0.00%
Number of warrants	62,500
Fair value of warrants | $	$ 229,921

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) - Schedule of Share-based Compensation, Stock Options, Activity (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Equity [Abstract]
Shares Outstanding, Beginning Balance | shares	1,362,500
Shares, Granted | shares	1,250,000
Shares, Forfeitures | shares
Shares, Expirations | shares
Shares, Exercised | shares
Shares Outstanding, Ending Balance | shares	2,612,500
Shares Exercisable, Ending Balance | shares	1,391,667
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 2.26
Weighted Average Exercise Price, Granted | $ / shares	2.11
Weighted Average Exercise Price, Forfeitures | $ / shares
Weighted Average Exercise Price, Expirations | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	3.28
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 2.41
Weighted Average Remaining Contractual Term (Years) Outstanding, Beginning Balance	3 years 9 months 11 days
Weighted Average Remaining Contractual Term (Years), Granted	2 years 3 months 15 days
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	4 years
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	3 years 5 months 16 days

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) - Schedule of Exercise Price of Options Outstanding and Exercisable (Details)	Jun. 30, 2019$ / sharesshares
Options Outstanding (Shares)	2,612,500
Options Exercisable (Shares)	1,391,667
Exercise Price One [Member]
Options Outstanding (Shares)	625,000
Options Exercisable (Shares)	625,000
Exercise Prices | $ / shares	$ 2
Exercise Price Two [Member]
Options Outstanding (Shares)	62,500
Options Exercisable (Shares)	62,500
Exercise Prices | $ / shares	$ 2.30
Exercise Price Three [Member]
Options Outstanding (Shares)	675,000
Options Exercisable (Shares)	600,000
Exercise Prices | $ / shares	$ 2.50
Exercise Price Four [Member]
Options Outstanding (Shares)	1,250,000
Options Exercisable (Shares)	104,167
Exercise Prices | $ / shares	$ 4.40

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Amortization of stock option awards	$ 1,066,159
Board Chairman And Chief Executive Officer [Member] | Michael Favish [Member]
Officers compensation	$ 150,000	$ 137,500